Published in Eur J Clin Pharmacol on August 12, 2003
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health (2008) 1.52
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet Genomics (2012) 1.50
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS (2012) 1.35
HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther (2009) 1.08
Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol (2007) 0.90
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. J Antimicrob Chemother (2010) 0.89
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi. Malawi Med J (2011) 0.87
Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women. Open AIDS J (2012) 0.86
Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients. PLoS One (2013) 0.81
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. Int J Mol Sci (2016) 0.79
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations. J Antimicrob Chemother (2014) 0.77
Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline. Antimicrob Agents Chemother (2014) 0.77
Antiviral drug allergy. Immunol Allergy Clin North Am (2014) 0.76
Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. Br J Clin Pharmacol (2006) 0.76
A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation. Open AIDS J (2009) 0.75
Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy. F1000Res (2015) 0.75
Toxic epidermal necrolysis - management issues and treatment options. Int J Burns Trauma (2011) 0.75
Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach. Eur J Clin Pharmacol (2016) 0.75
Hepatitis B virus infection. N Engl J Med (1997) 14.50
Adverse effects of antiretroviral therapy. Lancet (2000) 4.84
Cutaneous disease and drug reactions in HIV infection. N Engl J Med (1993) 2.89
Hepatitis C. Ann Intern Med (1996) 2.35
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS (2001) 2.12
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis (1995) 1.97
Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos (1999) 1.73
The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol (1997) 1.65
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother (1993) 1.62
Nevirapine-associated Stevens-Johnson syndrome. Lancet (1998) 1.53
Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl (1998) 1.13
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS (2000) 1.13
Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS (2001) 0.92
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis (1997) 0.89
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 0.85
Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr (2001) 0.82
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS (2001) 0.78
Experience with nevirapine in previously treated HIV-1-infected individuals. Antivir Ther (2000) 0.75
Prevention of nevirapine-associated rash. Lancet (2001) 0.75
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis (2013) 4.03
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed (2010) 2.34
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol (2011) 2.24
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother (2012) 2.14
Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.08
Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology (2010) 1.98
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res (2006) 1.95
Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 1.90
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS (2002) 1.84
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet (2005) 1.84
Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet (2004) 1.82
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging (2010) 1.69
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res (2006) 1.65
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem (2003) 1.63
Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell (2011) 1.62
Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol (2009) 1.61
Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol (2006) 1.60
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci (2005) 1.59
Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther (2005) 1.58
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother (2008) 1.58
Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet (2005) 1.57
Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol (2011) 1.55
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS (2003) 1.54
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol (2010) 1.53
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res (2004) 1.51
The effects of fall-risk-increasing drugs on postural control: a literature review. Drugs Aging (2013) 1.50
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol (2003) 1.49
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther (2005) 1.45
Clinical relevance of microparticles from platelets and megakaryocytes. Curr Opin Hematol (2010) 1.43
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet (2003) 1.43
Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist (2006) 1.43
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res (2009) 1.42
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol (2012) 1.41
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer (2011) 1.40
Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn Ther (2007) 1.39
Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci (2006) 1.36
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther (2008) 1.36
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res (2003) 1.32
Clinical experience with aurora kinase inhibitors: a review. Oncologist (2009) 1.31
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol (2006) 1.29
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics (2008) 1.28
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev (2004) 1.28
Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.28
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer (2005) 1.27
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.27
Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol (2008) 1.26
Dengue disease severity in Indonesian children: an evaluation of the World Health Organization classification system. BMC Infect Dis (2007) 1.26
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet (2006) 1.26
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res (2007) 1.24
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist (2005) 1.24
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol (2002) 1.23
Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist (2007) 1.23
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther (2010) 1.21
Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat (2008) 1.21
Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol (2006) 1.21
Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol (2006) 1.21
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res (2002) 1.21
Long pentraxin PTX3 is associated with mortality and disease severity in severe Leptospirosis. J Infect (2009) 1.18
Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data. BMC Bioinformatics (2008) 1.17
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist (2008) 1.17
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res (2003) 1.17
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res (2006) 1.17
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials (2005) 1.16
The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther (2004) 1.14